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Abstract: The feasibility of using chemosensitizers in the 
circumvention of P-glycoprotein-mediated multidrug resis- 
tance has been shown in many studies. We recently reported 
on the chemosensitizing effect of cyclosporin A (CsA) on 
doxorubicin i  a rat solid tumour model. Using the same ex- 
perimental design we investigated the side-effects of the 
combination treatment. During the 35-day experiment do- 
xorubicin treatment caused dose-dependent weight loss, 
which was enhanced by combination treatment with CsA. 
The main doxorubicin-related si e-effects were myelosup- 
pression (transient leucopenia nd thrombopenia) nd ne- 
phrotoxicity. Damage to the kidney was severe, leading to a 
nephrotic syndrome and resulting in ascites, pleural effusion, 
hypercholesterolaemia and hypertriglyceridaemia. These 
toxicities were enhanced by the addition of the chemosensi- 
tizer CsA. Mild doxorubicin-related cardiomyopathy and 
minimal hepatotoxicity were seen on histological examina- 
tion. There were no signs of enhanced toxicity of the combi- 
nation treatment in tissues with known high expression lev- 
els of P-glycoprotein, like the liver, adrenal gland and large 
intestine. CsA had a low toxicity profile, as it only caused a
transient rise in bilirubin. In conclusion, the chemosensitizer 
CsA enhanced the side-effects ofthe anticancer drug doxoru- 
bicin without altering the toxicity pattern. There was no evi- 
dence of a therapeutic gain by adding CsA to doxorubicin, 
compared to single-agent treatment with doxorubicin in 
25%-33% higher doses, because of the enhanced toxicity of 
the combination treatment. 
Key words: Chemosensitizer - Cyclosporin A - Doxorubi- 
cin - Multidrug resistance - Toxicity 
This work was supported by the Dr Daniel den Hoed Foundation, Rot- 
terdam, The Netherlands 
Abbreviations: CsA, cyclosporin A; DOX, doxorubicin; MDR, multi- 
drug resistance; PBS, phosphate-buffered saline 
Correspondence to: A.M.M. Eggermont, Department of Surgical On- 
cology, Rotterdam Cancer Institute, Groene Hilledijk 301, 3075 EA 
Rotterdam, The Netherlands 
Introduction 
Multidrug resistance (MDR) is an important mechanism of 
resistance of tumours to anticancer drugs. In MDR an efflux 
pump, P-glycoprotein, expels drugs from the cell by active 
transport (Chin et al. 1993). P-glycoprotein expression has 
been found in many tumours. High expression levels of P- 
glycoprotein were demonstrated in colon cancer, renal cell 
cancer, hepatocellular carcinoma, and adrenocortical cancer, 
while intermediate levels were found in sarcomas and breast 
cancer (Fojo et al. 1987; Goldstein et al. 1989). In haemato- 
logical malignancies, like several eukemias, lymphomas 
and in multiple myeloma, expression of P-glycoprotein was 
found in untreated and, to a greater extent, in treated tumours 
(Dalton et al. 1989; Goldstein et al. 1989; Herweijer et al. 
1990). However, this protein is also expressed in normal tis- 
sues. Organs with a high expression level of P-glycoprotein 
are the adrenal gland, liver, kidney, colon and pancreas (Fojo 
et al. 1987; Thiebaut et al. 1987), and the protein is mainly 
localized in cells lining excretory lumina, which suggests a
detoxification function (Thiebaut et al. 1987). 
One way of disturbing the P-glycoprotein-mediated resis- 
tance mechanism is by blocking the effiux pump with so-cal- 
led chemosensitizers. Numerous in vitro studies have shown 
the efficacy of drugs like verapamil, cyclosporin A (CsA), 
quinine/quinidine, tamoxifen and others in enhancing the 
sensitivity of MDR tumour cell lines to anticancer drugs 
(Ford and Hait 1990). In vivo studies have confirmed the fea- 
sibility of reversal of MDR by chemosensitizers in ascites tu- 
mour models (Tsuruo et al. 1981; Slater et al. 1986) and in 
solid tumour models (Osieka et al. 1986; Van de Vile et al. 
1993). In clinical trials promising results have been observed 
in patients with multiple myeloma, lymphoma nd leukemia 
(Dalton et al. 1989; Solary et al. 1992; Sonneveld et al. 1992; 
List et al. 1993). In studies with solid tumours chemosensiti- 
zers showed less efficacy with responses in a minority of the 
patients only (Miller et al. 1988; Bissett et al. 1991; Philip et 
al. 1992; Verweij et al. 1991). Besides, some authors have re- 
ported on enhancement of toxic side-effects, like myelosup- 
pression, by the addition of chemosensitizers to the therapeu- 
tic regimen (Fiqueredo et al. 1990; Verweij et al. 1991; 
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Yahanda et al. 1992). Therefore, the question is raised wheth- 
er the use of chemosensitizers in combination with antican- 
cer drugs enhances the toxic side-effects of these drugs, apart 
from enhancing the efficacy of the anticancer t eatment. A 
second question is whether other toxic effects will appear, es- 
pecially in P-glycoprotein-expressing tissues. Third, chemo- 
sensitizers themselves may have adverse ffects. 
We recently published our results on chemosensitizing i  
a rat MDR tumour model (Van de Vrie et al. 1993). The 
chemosensitizer CsA was shown to enhance the cytotoxic ef- 
ficacy of doxorubicin i  vitro and in vivo. A suboptimal dose 
of doxorubicin (3 mg/kg) was rendered effective against he 
solid growing CC531 rat colon carcinoma in vivo by the ad- 
dition of CsA. Drugs were administered intramuscularly and 
intravenously, which means that, unlike in ascites tumour 
models, drugs were transported to the tumour and other tis- 
sues by a vascular route. Because this is close to the clinical 
situation, the same model was used to study the toxic effects 
of the combination treatment on normal tissues in rats. In this 
study we show that the chemosensitizer CsA enhances the 
specific toxic effects of doxombicin on normal tissues, re- 
sulting in myelosuppression, severe nephrotoxicity and mild 
cardiotoxicity. There were no signs of additive toxic damage 
in tissues with a high expression level of P-glycoprotein, or 
of severe CsA-induced toxicity. 
Materials and methods 
Animals. Male rats of the inbred WAG/RIJ (RT1 ~) strain were obtained 
from Harlan-CPB (Ansterlitz, The Netherlands). Animals were bred un- 
der specific-pathogen-free conditions and fed standard rat chow (Hope 
Farms, Woerden, The Netherlands) and water ad libitum. In the experi- 
ments rats were 12-18 weeks old and had a body weight of 220-280 g. 
Chemicals. Cyclosporin A was obtained from Sandoz, Basel, Switzer- 
land; doxorubicin (Adriablastina) from Farmitalia, Nivelles, Belgium. 
Experimental design. Animals were randomly allocated to the experi- 
mental groups. The two control groups consisted ofeight animals, while 
the five experimental groups contained four animals each. The experi- 
ment was repeated once. Intravenous injection and blood sampling were 
done under anaesthetic conditions using ether. Rats were weighed week- 
ly. On days 3, 7, 14, 21, and 28 a blood sample of 0.75 ml was taken by 
bleeding from the tail vein. On the 35th day the experiment was termi- 
nated and all rats were sacrificed. If an animal was critically ill such that 
it was not supposed tosurvive 48 h, or if it had lost approximately 20% 
body weight, the animal was sacrificed earlier than day 35. 
Drug treatment. The chemosensitizer CsA, dissolved in olive oil, was 
injected intramuscularly into the hind leg daily for 3 consecutive days at 
a dose of 20 mg/kg body weight. Animals in groups not to be treated 
with CsA were injected with the vehicle of CsA: olive oil and 6.25% al- 
cohol. Treatment was given on days -2, -1 and 0. Doxorubicin was ad- 
ministered intravenously onday 0 as a single dose at a concentration f 
3 mg/kg, 4 mg/kg or 6 mg/kg body weight. Control rats were injected 
with phosphate-buffered saline (PBS). This resulted in the following 
groups: control (treatment with PBS and vehicle), CsA-con (PBS + 
CsA), DOX3 (3 mg/kg doxorubicin +vehicle), DOX3+CsA (3 mg/kg 
doxor~bicin + CsA), DOX4 (4mg/kg doxor~bieirl + vehicle), 
DOX4+CsA (4 mg/kg doxorubicin +CsA), and DOX6 (6 mg/kg dox- 
orubicin + vehicle). 
Haematological nd biochemical studies. Blood was collected in lithi- 
mrdheparin microtubes (Sarstedt, Germany). The haemoglobin content 
was determined on the TOA haemoglobin counter HB-100, leucocytes 
on the Sysmex microcell counter CC-108 and platelets on the TOA 
platelet counter PL-t00 (all Sysmex, TOA Medical Electronics, Ham- 
burg, Germany). The remaining blood sample was centrifuged and se- 
rum was collected. Biochemical values of creatinine, urea, aspartate 
aminotransferase, "/-glutamyltransferase, total bilirubin, cholesterol and 
triglyceride were determined onthe ELAN-Analyzer (Eppendorf, Ham- 
burg, Germany) with reagents from Merck (Merck Diagnostica, Darm- 
stadt, Germany). 
Histology. On day 35 all animals were sacrificed and an autopsy was 
performed. Ascites and pleural effusion, if present, were aspirated in a 
syringe and measured. Specimens ofthe following organs were taken for 
histological examination: heart, lung, liver, spleen, kidney, large intes- 
tine, pancreas and adrenal gland. The organs were removed immediate- 
ly, fixed in 10% buffered formalin and embedded inparaffin. Sections 
were cut at 5/.Lm, stained with haematoxylin a d eosin, and periodic ac- 
id/ Schiff. Microscopic sections were coded and scored blindly. The fol- 
lowing histological parameters were evaluated: oedema, necrosis, in- 
flammation, accumulation f fat, fibrosis, glycogen storage (liver) and 
degenerative changes. The extent of damage in kidney and liver was 
graded semiquantitatively on a 0 to 2+ scale (0 = absent, 1+ = slightly 
damaged, 2+ = severely damaged). The histopathological hanges inthe 
heart were assessed according to the scoring system of Bristow et al. 
(1982), which scale runs from 0 to 3.0+. 
Statistics. Statistical significance was determined with SPSS/PC+, us- 
ing the Mann-Whitney U/Wilcoxon Rank Sum WTest. P<0.05 was con- 
sidered significant. Results are presented asmeans with standard devia- 
tions. In the line diagrams standard deviations are omitted for readability 
reRsons .  
Ethical approval. The experimental protocols adhered to the roles laid 
down in The Dutch Animal Experimentation Act (1977) and the pub- 
lished Guidelines on the Protection of Experimental Animals by the 
Council of the EC (1986). Specific protocols were approved by the 
Committee on Animal Research of the Erasmus University, Rotterdam. 
Results 
Weight 
Drug treatment had a profound influence on the body weight 
of the animals. In the first experiment rats treated with the 
highest doses of doxorubicin and doxorubicin plus CsA did 
not survive for 35 days (Fig. 1), whereas in the repeat exper- 
iment under the same conditions none of the rats died before 
the end of the experiment. The maximal tolerable dose of 
doxorubicin in WAG rats is 4 mg/kg. We purposely chose to 
administer a higher dose for the comparison of toxic side-ef- 
fects. Rats treated with the highest doses of doxorubicin de- 
veloped ascites, which made body weight a less reliable pa- 
rameter towards the end of the experiment for comparison of 
groups. Therefore, significance of the differences is deter- 
mined for day 21. All control rats continued to grow during 
the experiment, while rats treated with doxorubicin lost 
weight. This effect was most pronounced in the groups 
DOX6 and DOX4+CsA. The weight curves of the groups 
DOX3+CsA and DOX4 ran down in parallel, while the 
DOX3 group fared better. 
Haematological parameters 
Drug treatment had no effect on haemoglobin during the first 
14 days (data not shown). The nadir for leucocytes and 
thrombocytes was reached around ay 7 (Table 1). A signifi- 
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Fig. 1. Body weight changes of rats under treatment with doxorubicin 
(DOX) with or without cyclosporin A (CsA). +, control; x, CsA-con; 
~, DOX3; A, DOX3+CsA; O, DOX4; V, DOX4+CsA; N, DOX6 (see 
Materials and methods for definitions of the groups). Statistically signif- 
icant differences determined on day 21 are: DOX6 versus DOX4+CSA, 
DOX4, DOX3+CsA, DOX3, CsA-con and control; DOX4+CsA versus 
DOX4, DOX3+CsA, DOX3, CsA-con, and control; DOX4 versus 
DOX3, CsA-con, and control; DOX3+CsA versus DOX3, CsA-con and 
control (all P<0.025) 
Table 1. Blood parameters determined on day 7 
Group Leucocytes Thrombocytes Bilirubin 
Control 7.76 (_+0.75) 545 (_+39) 2.39 (_+0.28) 
CsA-con 6.96 (_+0.66) 497 (+_33) 3.49 (_+0.45) .8
DOX3 5.90 (+_1.80) 3' 575 (_+50)*' 1.60 (_+0.88) 
DOX3+CsA 4.68 (+1.06) .2 414 (-+98) *5 2.35 (-+0.10) 
DOX4 5.40 (_+1.68) *3 415 (+74) ~6 1.65 (-+0.17) 
DOX4+CsA 2.93 (_+0.25) ~4 246 (+38) *4 2.08 (-+0.61) 
DOX6 3.20 (_+0.50) *4 129 (_+t0) *7 1.58 (_+0.30) 
The groups are defined in Materials and methods 
*'-*sSignificance was determined atthe P<0.05 level: *~ not significantly 
lower than control groups; ,2 significantly lower than both control 
groups; " significantly lower than control; ,4 significantly lower than 
control groups and DOX3, DOX3+CsA and DOX4; ,5 significantly ow- 
er than control and DOX3; ,6 significantly lower than control groups and 
DOX3; ,7 significantly lower than all other groups; ,8 significantly high- 
er than all other groups 
cant drop in leucocyte and platelet count was observed in all 
drug-treated groups except DOX3.  In the groups 
DOX3+CsA and DOX4 approximately equal levels of  
leucocytes and platelets were found. The same holds good 
for leucocytes in the groups DOX4+CsA and DOX6.  The 
DOX4+CsA group had a signif icant lower nadir compared to 
the DOX4 group for both haematological  parameters. 
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Fig. 2. a Cholesterol concentrations i  rats treated with doxorubicin with 
or without cyclosporin A. Statistical significance between the groups is 
determined for day 14. All treated groups are significantly different from 
both control groups (P<0.01); DOX4+CsA versus DOX6, DOX4 and 
DOX3 (P<0.025); DOX3+CsA versus DOX3 and DOX4 (P<0.05; 
DOX6 versus DOX3 (P<0.025). h Triglyceride concentrations in rats 
treated with doxorubicin with or without cyclosporin A. Statistical sig- 
nificance between the groups is determined for day 14. All treated 
groups are significantly different from both control groups (P<0.01); 
DOX4+CsA versus DOX6, DOX4 and DOX3 (P<0.05); DOX3+CsA 
versus DOX3 (P<0.05). +, Control; x, CsA-con; ~, DOX3; A, 
DOX3+CsA; 0, DOX4; Y, DOX4+CsA; N, DOX6 
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Fig. 3. Nephrotoxicity caused by doxorubicin treatment: thickening of
the basement membrane, mesangial hypercellularity, accumulation f 
lipids and adhesion to Bowman's capsule. Original magnification 400x; 
H&E staining 
Lipid biochemical values 
Doxorubicin had a profound influence on the lipid metabo- 
lism in WAG rats. All treated groups had increased levels of 
serum cholesterol and triglyceride (Fig. 2a,b). The rise con- 
tinued for 14-21 days and was amplified by CsA: in the 
DOX4+CsA and DOX3+CsA groups the highest levels were 
observed. CsA alone had no influence on cholesterol and 
triglyceride l vels. 
The high levels of lipids disturbed the measurement of 
other haematological nd biochemical values from 14 days 
onwards. Therefore, we were only able to determine the 
short-term effects of the treatment on these values. 
Renal biochemical values 
During the first 14 days no significant changes in creatinine 
and urea were observed (data not shown). 
Liver biochemical values 
Doxorubicin treatment had no short-term effect on the liver 
function parameters aspartate aminotransferase and 7-glut- 
amyltransferase (data not shown). A significant rise in biliru- 
bin was observed in the CsA control group (Table 1). This 
cyclosporin-related effect seemed to be mitigated by combi- 
nation treatment with doxorubicin. 
Autopsy 
Pathology data presented here are from the second experi- 
ment, in which all animals survived. On day 35, rats in the 
groups DOX4+CsA and DOX6 were critically ill. They had 
lost body weight and subcutaneous fat. During the experi- 
ment rats had not had diarrhoea. At autopsy alarge amount of 
ascites and haemorrhagic pleural effusion was found in rats 
treated with DOX4+CsA and DOX6. Rats in the 
DOX4+CsA group had 12.4 (+12.4)ml ascites, rats in the 
DOX6 group 15.3 (+6.9) ml, while only a small amount of 
2.1 (+2.4) ml was found in the DOX3+CsA group and no as- 
cites in the other ats. Pleural effusion was 6.5 (+3.1) ml and 
6.3 (+4.4) ml in the DOX4+CsA and DOX6 groups respec- 
tively. In the DOX3+CsA group 0.8 (+1.5) ml pleural effu- 
sion was found and none in the other ats. The differences in
ascites and pleural effusion were statistically significant for 
the DOX4+CsA and DOX6 groups compared to all other 
groups except for pleural effusion in DOX6 versus 
DOX3+CsA. In addition, oedema of the pancreas and pale- 
ness of the liver, kidneys and adrenal glands were observed 
in rats of the DOX4+CsA and DOX6 groups. In the other 
groups all these macroscopic findings were minimal or ab- 
sent. 
Microscopic study 
Light-microscopic examination ofthe kidney showed severe 
damage (2+) in all rats treated with doxorubicin or the com- 
bination doxorubicin and CsA, while rats injected with PBS 
or CsA had normal kidneys. Injured kidneys showed in- 
creased glomerular mesangial cellularity, lipid accumulation 
in macrophages, thickening of basement membranes of glo- 
merular capillaries and Bowman's capsule with in some glo- 
meruli focal adhesions (Fig. 3). The tubule epithelium 
showed degenerative changes, focal regenerative activity 
(mitotic figures) and some showed protein casts. In the inter- 
stitial space of injured kidneys focal lymphocytic infiltrates 
were seen. Blood vessels had normal morphology. 
The myocardium of rats treated with doxorubicin and the 
combination doxorubicin plus CsA showed minimal mor- 
phological changes with oedema in the interstitial space, 
slight vacuolisation of myocytes, and sporadic focal inflam- 
mation. Necrosis or fibrosis was not observed. The maximal 
score according to Bristow et al. (1982) was 1.5. Increased 
doses of doxorubicin revealed the same degree of damage; 
however, a greater percentage of rats in each group was af- 
fected with higher doses (DOX3 25%; DOX3+CsA 50%; 
DOX4 75%; DOX4+CsA and DOX6 100%). 
Minimal hepatotoxic changes were demonstrated. In rats 
treated with DOX4 and DOX6 mononuclear inflammation 
and spotty necrosis were observed with a reduced amount of 
glycogen (score 2+). Rats treated with the combination 
doxorubicin and CsA showed slight morphological changes 
(score 1+) with minor inflammation and sporadic necrotic 
hepatocytes. 
Histological examination of the colon demonstrated 
oedema in the mucosa of rats treated with doxorubicin and 
the combination doxorubicin plus CsA, while inflammation 
or necrosis was absent in this experiment. The lung paren- 
chyma showed some focal inflammatory aggregates not re- 
lated to the bronchial tree in rats treated with DOX4 and 
DOX6. The spleen showed slight hypoplasia of the white 
pulpa in the groups with DOX6 and the combination dox- 
orubicin plus CsA. Pancreas and adrenal glands showed nor- 
mal histology. The findings in colon, lung and spleen, how- 
ever, were not observed consistently in all rats within the 
same treatment group, and differences between the groups 
were minimal. 
Discussion 
The addition of the chemosensitizer CsA to the anticancer 
drug doxorubicin clearly enhances its toxicity. In a previous 
study we demonstrated that the addition of CsA made a sub- 
optimal dose of 3 mg/kg doxorubicin as effective as 4 mg/kg 
doxorubicin (Van de Vrie et al. 1993). In the present study we 
show data (body weight change curves, haematological pa- 
rameters, and autopsy findings) indicating that the combina- 
tion of doxorubicin with CsA is about as toxic as a 25%-33% 
higher doxorubicin dose alone. We found therefore no thera- 
peutic window, in contrast to Mickisch et al. (1991) in their 
transgenic mouse model. They had to reduce the dose of 
most anticancer drugs by 20%, while these doses in combi- 
nation with D-verapamil reduced MDR cell populations by 
44%-78%. The results of the combination treatment were fa- 
vourable compared to results with full doses of the drugs 
alone. Boesch et al. (1991) reported similar favourable re- 
sults of a combination treatment of vinblastine and dox- 
orubicin with the CsA analogue PSC 833 in a survival model 
of mice with MDR turnouts. 
The toxicity pattern of doxorubicin is not altered by the 
addition of CsA. Doxorubicin, like most other cytotoxic 
agents, causes severe damage to cell-renewal systems, 
which are highly proliferative in postfetal life (Philips et al. 
1975). In our experiments he main acute side-effect was 
myelosuppression with significant leucopenia nd throm- 
bopenia. This effect was reversible. No signs of enterocoli- 
tis were observed. Unique toxic actions of anthracyclines, 
especially doxorubicin, are cardiovascular toxic effects, ne- 
phrotoxicity and toxic effects on the skeletal system. The 
last two effects can be observed in several experimental 
models, while cardiotoxicity is also found in humans 
(Young 1975). In man cardiomyopathy leading to conges- 
tive heart failure is dependent on the total cumulative dose 
administered (Lenaz and Page 1976). Our study was not de- 
signed specifically for studying the toxic effects of dox- 
orubicin on cardiac tissue. The study was short-term, last- 
ing only 35 days, and involved a single-dose treatment 
schedule for doxorubicin, which made it more apt for 
studying acute toxic effects than chronic damage. Never- 
theless, on microscopic examination mild damage to the 
cardiac tissue was observed in the most intensely treated 
rats. Other investigators have found severe cardiomyopathy 
in rats from 35 days onwards after administering multiple 
low doses of doxorubicin instead of a single high dose, and 
reaching higher cumulative values for doxorubicin than we 
did (Mettler et al. 1977; Van Hoesel et al. 1986). Results in 
studies with clogs and mice suggest that the addition of the 
chemosensitizer verapamil potentiates the cardiotoxic ef- 
fects of doxorubicin (Bright and Buss 1990; Sridhar et al. 
1992). 
WAG rats proved to be very sensitive to the nephrotoxic 
effects of doxorubicin, eventually developing a full-blown 
nephrotic syndrome (Young 1975; Van Hoesel et al. 1986). 
We were unable to measure proteins and renal parameters af- 
ter 14 days because of disturbance ofthe assay caused by tur- 
bidity of the hyperlipidaemic serum, but the ascites and pleu- 
ral effusion indicate hypoproteinaemia. Levels of cholesterol 
and triglyceride were significantly raised by doxorubicin. 
Addition of CsA raised the levels of cholesterol and triglyce- 
537 
ride even higher, in such a way that combination treatment 
produced the highest levels. Meanwhile, significant amounts 
of ascites and pleural effusion were only found in the two 
most intensely treated groups. This indicates that he nephro- 
toxic effects of doxorubicin were amplified by the chemo- 
sensitizer CsA. 
Tissues with known high expression levels of P-glyco- 
protein, like liver, large intestine and adrenal gland, were 
monitored for toxic effects. No signs of major toxicity were 
observed. This suggests that these tissues are not suscepti- 
ble to the cytotoxic effects of doxorubicin, and that raising 
its intracellular concentration, either by administering a 
higher dose, or by adding a chemosensitizer, does not make 
these tissues ensitive to doxorubicin, despite the presence 
of P-glycoprotein. Other esearchers have come to the same 
conclusion in a pathology study using the chemosensitizer 
D-verapamil and the drugs vinblastine, doxorubicin, and 
daunomycin (Mickisch et al. 1991). In contrast, Horton et 
al. (1989) found enhanced concentrations of vincristine in 
P-glycoprotein-expressing normal tissues, like small intes- 
tine, kidney and liver, caused by the addition of high doses 
of the chemosensitizer verapamil. Toxicity was enhanced 
eightfold and symptomatic of vincristine-related neurotox- 
icity. They did not describe the functional and morphologi- 
cal effects of the raised concentration of intracellular 
vincristine in these normal tissues. Genne et al. (1989) also 
reported enhanced oxorubicin accumulation i  kidney and 
liver in combination treatment with the chemosensitizer 
amiodarone. Combination treatment accelerated dox- 
orubicin-induced death. In clinical studies with chemosen- 
sitizers, however, no toxicities, apart from those attribut- 
able to the drug or the chemosensitizer, have been observed 
so far. 
CsA seems to produce few toxic effects in the concentra- 
tions used for chemosensitizing. In clinical trials steady-state 
levels from 1000 gg/1 up to 5000 gg/1 were reported (Verweij 
et al. 1991; Sonneveld et al. 1992; Yahanda et al. 1992; List 
et al. 1993). The CsA concentration f 1000 pg/1 suffices in 
vitro for MDR reversal. Side-effects of CsA observed were 
an early and transient rise in serum bilirubin, without in- 
creases in liver enzymes, and hypomagnesaemia (Lure et al. 
1992; Sonneveld et al. 1992; Yahanda et al. 1992; List et al. 
1993). In our rat study the transient hyperbilirubinaemia ap-
peared to be a purely CsA-dependent feature, which was not 
enhanced by the addition of doxorubicin. We found no evi- 
dence in our rat model for the hypothesis that bilirubin is rai- 
sed as a consequence of competition between doxorubicin, 
CsA, and bilirubin at the excretion level, and thus might be 
used as a marker for P-glycoprotein modulation in vivo 
(Yahanda et al. 1992; List et al. 1993). 
From our studies with doxorubicin and cyclosporin it can 
be concluded that the addition of a chemosensitizer s riously 
enhances the toxic side-effects ofthe anticancer drug without 
altering the pattern of toxicity. As the toxicity patterns of an- 
ticancer drugs are known, side-effects can be anticipated in
the planning of clinical trials. However, it remains unclear 
from this study whether therapeutic gains can be made by the 
application of a chemosensitizer. 
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